A Randomized, Double-blind, Multi-dose, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate to Severe Chronic Low Back Pain
Phase of Trial: Phase II/III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Fasinumab (Primary) ; Fasinumab (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 26 Jul 2017 This trial status has been changed from Suspended to completed in Denmark as per European Clinical Trials Database record.
- 16 Nov 2016 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
- 16 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2017.